Flexbumin: - Discard product if it contains particulate matter, is cloudy, or discolored - Discard unused portion. Macrotec: - Refrigerate between 36 and 46 degrees F Plasbumin: - Avoid temperatures above 86 degrees F - Discard product if it contains particulate matter, is cloudy, or discolored - Discard unused portion. Use of albumin is contraindicated in patients with a history of albumin hypersensitivity or hypersensitivity to any of the excipients. Discontinue administration immediately and institute appropriate medical treatment if a hypersensitivity reaction is suspected.
Albumin is contraindicated in patients with severe anemia or heart failure with normal or increased intravascular volume. Monitor coagulation and hematology parameters when large volumes are replaced. Ensure adequate substitution of other blood constituents e. Monitor electrolyte status and take appropriate steps to address electrolyte imbalance.
Discontinue albumin administration at the first sign of cardiovascular overload e. Albumin increases plasma volume and can cause vascular overload, especially after rapid infusion. Monitor blood pressure in trauma and postoperative surgery patients in order to detect rebleeding secondary to clot disruption. Closely monitor hemodynamic parameters for evidence of increased intracranial pressure and cardiac, respiratory, or renal failure in all patients.
Accumulation at concentrations associated with central nervous system and bone toxicity is more likely to occur in patients with renal disease or in premature neonates with immature kidneys. Albumin is a derivative of human blood. As with other products derived from or purified with human blood components, the remote possibility of contamination with Creutzfeldt-Jakob disease CJD or other viral infections exists in patients receiving albumin.
The manufacturing processes are designed to reduce the risk of transmitting viral infection. No cases of transmission of viral illness or CJD have ever been identified for albumin.
Report all infections thought to have been transmitted by albumin to the manufacturer. Patients with marked dehydration require the administration of additional fluids when treated with concentrated albumin.
Monitor patients carefully to guard against circulatory overload and hyperhydration. It is not known whether albumin products can cause fetal harm or affect reproductive capacity when administered to a pregnant woman. No human or animal data are available to indicate the presence or absence of drug-associated risk with albumin use during pregnancy. It is not known whether albumin is excreted in human milk. No human or animal data are available to indicate the presence or absence of drug-associated risk with albumin use while breast-feeding.
Exogenously administered albumin increases the oncotic pressure of the intravascular system, pulling fluids from the interstitial space, thereby decreasing edema and increasing the circulating blood volume.
This increase in volume reduces the concentration and viscosity of blood in patients with decreased circulating blood volume and also maintains cardiac output in shock. In dehydrated patients, albumin has little or no clinical effect on circulating blood volume.
Albumin is also used to replace protein in patients with hypoproteinemia until the cause of the deficiency can be determined. It is distributed only in the intravascular space. Albumin solutions have a plasma half-life of 16 to 24 hours and a duration of volume expansion of 12 to 24 hours. When administered to patients with diminished blood volume, the effect of infused albumin may last for many hours; however, the duration is much shorter in patients with normal blood volume.
In a kg patient, total blood albumin is approximately g. PDR Search. Required field. Your Name Your name is required. Recipient's Email Separate multiple email address with a comma Please enter valid email address Recipient's email is required. Thank you. Your email has been sent. Jump to Section. Related Drug Information Drug Summary. Infants and Children. It is also used to treat hemolytic disease of the newborn HDN in babies. There is a problem with information submitted for this request.
Sign up for free, and stay up-to-date on research advancements, health tips and current health topics, like COVID, plus expert advice on managing your health. Error Email field is required. Error Include a valid email address. To provide you with the most relevant and helpful information and to understand which information is beneficial, we may combine your e-mail and website usage information with other information we have about you.
If we combine this information with your PHI, we will treat all of that information as PHI, and will only use or disclose that information as set forth in our notice of privacy practices. You may opt-out of e-mail communications at any time by clicking on the Unsubscribe link in the e-mail.
Our Housecall e-newsletter will keep you up-to-date on the latest health information. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes. Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission. Any use of this site constitutes your agreement to the Terms and Conditions and Privacy Policy linked below.
0コメント